These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 32387055)

  • 1. Timing of Peak Vision Gains in Patients with Neovascular Age-Related Macular Degeneration Treated with Ranibizumab.
    Khurana RN; Chang L; Day BM; Ghanekar A; Stoilov I
    Ophthalmol Retina; 2020 Aug; 4(8):760-766. PubMed ID: 32387055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab Treatment for Pigment Epithelial Detachment Secondary to Neovascular Age-Related Macular Degeneration: Post Hoc Analysis of the HARBOR Study.
    Sarraf D; London NJ; Khurana RN; Dugel PU; Gune S; Hill L; Tuomi L
    Ophthalmology; 2016 Oct; 123(10):2213-24. PubMed ID: 27566855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
    Lally DR; Hill L; Amador-Patarroyo MJ
    Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD.
    Waldstein SM; Wright J; Warburton J; Margaron P; Simader C; Schmidt-Erfurth U
    Ophthalmology; 2016 Jan; 123(1):60-9. PubMed ID: 26481821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of Early and Delayed Visual Response to Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration.
    Stoller GL; Kokame GT; Dreyer RF; Shapiro H; Tuomi LL
    JAMA Ophthalmol; 2016 May; 134(5):545-553. PubMed ID: 27010625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision.
    Frenkel RE; Shapiro H; Stoilov I
    Br J Ophthalmol; 2016 Aug; 100(8):1052-7. PubMed ID: 26541435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Ho AC; Busbee BG; Regillo CD; Wieland MR; Van Everen SA; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2014 Nov; 121(11):2181-92. PubMed ID: 25015215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
    Sadda SR; Tuomi LL; Ding B; Fung AE; Hopkins JJ
    Ophthalmology; 2018 Jun; 125(6):878-886. PubMed ID: 29477692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
    Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scheduled versus Pro Re Nata Dosing in the VIEW Trials.
    Richard G; Monés J; Wolf S; Korobelnik JF; Guymer R; Goldstein M; Norenberg C; Sandbrink R; Zeitz O
    Ophthalmology; 2015 Dec; 122(12):2497-503. PubMed ID: 26477840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With Neovascular Age-Related Macular Disease: A Randomized Clinical Trial.
    Kertes PJ; Galic IJ; Greve M; Williams G; Baker J; Lahaie M; Sheidow T
    JAMA Ophthalmol; 2020 Mar; 138(3):244-250. PubMed ID: 31917441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
    Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
    Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. End-of-Study Results for the Ladder Phase 2 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration.
    Khanani AM; Callanan D; Dreyer R; Chen S; Howard JG; Hopkins JJ; Lin CY; Lorenz-Candlin M; Makadia S; Patel S; Tam T; Gune S;
    Ophthalmol Retina; 2021 Aug; 5(8):775-787. PubMed ID: 33217618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration.
    Busbee BG; Ho AC; Brown DM; Heier JS; Suñer IJ; Li Z; Rubio RG; Lai P;
    Ophthalmology; 2013 May; 120(5):1046-56. PubMed ID: 23352196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response of vascular pigment epithelium detachment due to age-related macular degeneration to monthly treatment with ranibizumab: the prospective, multicentre RECOVER study.
    Clemens CR; Wolf A; Alten F; Milojcic C; Heiduschka P; Eter N
    Acta Ophthalmol; 2017 Nov; 95(7):683-689. PubMed ID: 28084038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
    Brown DM; Chen E; Mariani A; Major JC;
    Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.